{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:45:22Z","timestamp":1793882722070,"version":"4.7.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Imaging"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcmg.2024.11.003","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T23:43:58Z","timestamp":1740095038000},"page":"602-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Development of Imaging Endpoints for\u00a0Clinical Trials in AL and ATTR\u00a0Amyloidosis"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-1185","authenticated-orcid":false,"given":"Sharmila","family":"Dorbala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalyn","family":"Adigun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Brambatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.M.","family":"Cuddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preston","family":"Dunnmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar F.","family":"Abou Ezzeddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney H.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-2078","authenticated-orcid":false,"given":"Mariana","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin L.","family":"Grodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jerosch-Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Alex","family":"Hofling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Mittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina C.","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Race","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6424-4413","authenticated-orcid":false,"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Sirac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem","family":"Soman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett W.","family":"Sperry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman L.","family":"Stockbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lousada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmg.2024.11.003_bib1","unstructured":"Amyloidosis Research Consortium. ARC. Accessed February 20, 2025. www.arci.org"},{"key":"10.1016\/j.jcmg.2024.11.003_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13023-020-01525-2","article-title":"The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis","volume":"15","author":"Lousada","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcmg.2024.11.003_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jcmg.2024.11.003_bib4","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1007\/s12325-023-02637-4","article-title":"Peripheral nervous, hepatic, and gastrointestinal endpoints for AL amyloidosis clinical trials: report from the Amyloidosis Forum Multi-organ System Working Group","volume":"40","author":"Mauermann","year":"2023","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.jcmg.2024.11.003_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038","article-title":"Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the Amyloidosis Forum Cardiac Working Group","volume":"15","author":"Maurer","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jcmg.2024.11.003_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/PROM.S399658","article-title":"Health-related quality of life instruments for clinical trials in AL amyloidosis: report from the Amyloidosis Forum HRQOL Working Group","volume":"14","author":"Rizio","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.jcmg.2024.11.003_bib7","article-title":"Potential pathways for development of imaging endpoints for clinical trials in AL and ATTR amyloidosis","year":"2022","journal-title":"The Amyloidosis Forum: November 18"},{"key":"10.1016\/j.jcmg.2024.11.003_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jcmg.2024.11.003_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1750-1172-7-54","article-title":"Al amyloidosis","volume":"7","author":"Desport","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcmg.2024.11.003_bib10","first-page":"472","article-title":"A\u00a0modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jcmg.2024.11.003_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2024.11.003_bib12","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.3324\/haematol.2017.178095","article-title":"Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis","volume":"103","author":"Manwani","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jcmg.2024.11.003_bib13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar","year":"2021","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jcmg.2024.11.003_bib14","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.11.003_bib15","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jcmg.2024.11.003_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2024.11.003_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2024.11.003_bib18","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s40120-023-00522-4","article-title":"Impact of vutrisiran on quality of life and physical function in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"12","author":"Obici","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.jcmg.2024.11.003_bib19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2024.11.003_bib20","first-page":"442","article-title":"Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms","volume":"4","author":"Gonzalez-Lopez","year":"2022","journal-title":"JACC: CardioOncol"},{"key":"10.1016\/j.jcmg.2024.11.003_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jcmg.2024.11.003_bib22","article-title":"Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence","year":"2023","journal-title":"Guidance for Industry"},{"key":"10.1016\/j.jcmg.2024.11.003_bib23","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1182\/blood-2021-146782","article-title":"A\u00a0transgenic mouse model of cardiac AL amyloidosis","volume":"138","author":"Martinez-Rivas","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcmg.2024.11.003_bib24","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1038\/s41467-021-27416-z","article-title":"Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis","volume":"12","author":"Slamova","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcmg.2024.11.003_bib25","series-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]","article-title":"FDA-NIH Biomarker Working Group","year":"2016"},{"key":"10.1016\/j.jcmg.2024.11.003_bib26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.jcmg.2024.11.003_bib27","series-title":"Steps to validation of early endpoints to support drug development in neuroblastoma: key concepts","author":"McShane","year":"2022"},{"key":"10.1016\/j.jcmg.2024.11.003_bib28","series-title":"Eur J Heart Fail","first-page":"512","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","author":"Garcia-Pavia","year":"202123"},{"key":"10.1016\/j.jcmg.2024.11.003_bib29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization","volume":"27","author":"Dorbala","year":"2020","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.jcmg.2024.11.003_bib30","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to image cardiac amyloidosis: a practical approach","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/heartjnl-2015-308657","article-title":"Prognostic implication of relative regional strain ratio in cardiac amyloidosis","volume":"102","author":"Senapati","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jcmg.2024.11.003_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ehjci\/jeac057","article-title":"Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.006588","article-title":"Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis","volume":"11","author":"Milani","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/eurheartj\/ehab507","article-title":"Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis","volume":"43","author":"Cohen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2024.11.003_bib35","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ehjci\/jew298","article-title":"Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis","volume":"18","author":"Salinaro","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib36","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjh.18645","article-title":"Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light-chain amyloidosis","volume":"201","author":"Cohen","year":"2023","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jcmg.2024.11.003_bib37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: an analysis of the APOLLO study","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jcmg.2024.11.003_bib38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jcmg.2024.11.003_bib39","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib40","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood-2018-99-118464","article-title":"Improvement in Global Longitudinal Strain (GLS) correlates with NT-proBNP response in patients with cardiac amyloidosis treated on a phase 1b study of anti-amyloid Mab Cael-101","volume":"132","author":"Bhutani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jcmg.2024.11.003_bib41","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2024.11.003_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib43","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2024.11.003_bib45","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.11.003_bib46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCIMAGING.112.978627","article-title":"Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study","volume":"6","author":"Banypersad","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib47","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","article-title":"CMR-verified regression of cardiac AL amyloid after chemotherapy","volume":"11","author":"Martinez-Naharro","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib48","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1093\/eurheartj\/ehac363","article-title":"Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment","volume":"43","author":"Martinez-Naharro","year":"2022","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jcmg.2024.11.003_bib49","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jcmg.2023.02.019","article-title":"Tracking multiorgan treatment response in systemic AL-amyloidosis with cardiac magnetic resonance derived extracellular volume mapping","volume":"6","author":"Ioannou","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib50","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.121.012506","article-title":"Cardiac magnetic resonance\u2013derived extracellular volume mapping for the quantification of hepatic and splenic amyloid","volume":"14","author":"Chacko","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib51","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib52","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0002-8703(82)90331-3","article-title":"Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis","volume":"103","author":"Wizenberg","year":"1982","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcmg.2024.11.003_bib53","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2024.11.003_bib54","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","volume":"24","author":"Rettl","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib55","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2967\/jnumed.122.265352","article-title":"Regression of myocardial (99m)Tc-DPD uptake after tafamidis treatment of cardiac transthyretin amyloidosis","volume":"64","author":"Papathanasiou","year":"2023","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jcmg.2024.11.003_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102019","article-title":"Quantitative (99m)Tc-pyrophosphate myocardial uptake: changes on transthyretin stabilization therapy","volume":"39","author":"Vijayakumar","year":"2024","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.jcmg.2024.11.003_bib57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib58","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","article-title":"Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid","volume":"18","author":"Hutt","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","article-title":"Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis","volume":"4","author":"Rapezzi","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib60","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","article-title":"Diagnostic accuracy of [(11)C]PIB positron emission tomography for detection of cardiac amyloidosis","volume":"13","author":"Rosengren","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib61","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: a pilot study using (18)F-florbetapir positron emission tomography","volume":"41","author":"Dorbala","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib62","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","article-title":"[18F]-Florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions","volume":"14","author":"Genovesi","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/13506129.2020.1760237","article-title":"Quantification of cardiac amyloid with [(18)F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis","volume":"27","author":"Mockelind","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.jcmg.2024.11.003_bib64","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","article-title":"Cardiac amyloid quantification using (124)I-evuzamitide ((124)I-P5+14) versus (18)F-florbetapir: a pilot PET\/CT study","volume":"16","author":"Clerc","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib65","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.2967\/jnumed.122.264866","article-title":"Molecular imaging of systemic and cardiac amyloidosis: recent advances and focus on the future","volume":"64","author":"Dorbala","year":"2023","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jcmg.2024.11.003_bib66","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2967\/jnumed.118.221770","article-title":"Early detection of multiorgan light-chain amyloidosis by whole-body (18)F-Florbetapir PET\/CT","volume":"60","author":"Ehman","year":"2019","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jcmg.2024.11.003_bib67","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00259-018-3995-2","article-title":"Extracardiac (18)F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds","volume":"45","author":"Wagner","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib68","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jacc.2019.11.037","article-title":"Pittsburgh B compound positron emission tomography in patients with AL cardiac amyloidosis","volume":"75","author":"Lee","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.11.003_bib69","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2967\/jnumed.121.263033","article-title":"Independent prognostic utility of (11)C-Pittsburgh Compound B PET in patients with light-chain cardiac amyloidosis","volume":"63","author":"Choi","year":"2022","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jcmg.2024.11.003_bib70","article-title":"Prognostic value of left ventricular (18) F-Florbetapir uptake in systemic light-chain amyloidosis","author":"Clerc","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.jcmg.2024.11.003_bib71","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","article-title":"Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease?","volume":"13","author":"Cuddy","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.11.003_bib72","first-page":"2956","article-title":"Iodine-124-Evuzamitide PET\/CT in systemic amyloidosis: safety evaluation & reproducibility of cardiac uptake quantitation","volume":"30","author":"Bell","year":"2023","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.jcmg.2024.11.003_bib73","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/PROM.S411721","article-title":"The Transthyretin Amyloidosis - Quality of Life (ATTR-QOL) Questionnaire: development of a conceptual model and disease-specific patient-reported outcome measure","volume":"14","author":"O'Connor","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"issue":"8","key":"10.1016\/j.jcmg.2024.11.003_bib74","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2023.11.016","article-title":"Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis","volume":"30","author":"Masri","year":"2023","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jcmg.2024.11.003_bib75","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2024.11.003_bib76","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137036","article-title":"The prognostic importance of the 6-minute walk test in AL amyloidosis","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcmg.2024.11.003_bib77","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.jcmg.2024.11.003_bib78","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/13506129.2015.1102131","article-title":"The patient's perspective on the symptom and everyday life impact of AL amyloidosis","volume":"22","author":"Lin","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.jcmg.2024.11.003_bib79","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light chain (AL) amyloidosis: the journey to diagnosis","volume":"11","author":"McCausland","year":"2018","journal-title":"Patient"},{"key":"10.1016\/j.jcmg.2024.11.003_bib80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13023-016-0564-2","article-title":"The burden of amyloid light chain amyloidosis on health-related quality of life","volume":"12","author":"Bayliss","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcmg.2024.11.003_bib81","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jcmg.2024.11.003_bib82","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bjh.14889","article-title":"A\u00a0longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time","volume":"179","author":"Sanchorawala","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcmg.2024.11.003_bib83","article-title":"Patient-reported outcome measures: use in medical product development to support labeling claims","year":"2009","journal-title":"Guidance for industry"},{"issue":"12","key":"10.1016\/j.jcmg.2024.11.003_bib84","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jchf.2024.07.007","article-title":"Functional status and quality of life in light-chain amyloidosis: advanced imaging, longitudinal changes, and outcomes","volume":"12","author":"Clerc","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"22","key":"10.1016\/j.jcmg.2024.11.003_bib85","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2024.11.003_bib86","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.hoc.2020.08.003","article-title":"The impact of AL amyloidosis: the patient experience","volume":"34","author":"Lousada","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jcmg.2024.11.003_bib87","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ahj.2015.02.006","article-title":"Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography","volume":"169","author":"Masri","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcmg.2024.11.003_bib88","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.11.003_bib89","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcmg.2024.11.003_bib93","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/d41573-022-00158-3","article-title":"Accelerating therapeutic discoveries for heart failure: a new public-private partnership","volume":"21","author":"Shah","year":"2022","journal-title":"Nat Rev Drug Discov"}],"container-title":["JACC: Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936878X25000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936878X25000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:30:48Z","timestamp":1762597848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936878X25000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1936878X25000233"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmg.2024.11.003","relation":{},"ISSN":["1936-878X"],"issn-type":[{"value":"1936-878X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Imaging Endpoints for\u00a0Clinical Trials in AL and ATTR\u00a0Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmg.2024.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}